Get the Stockscreener App
11.42
0.79%
0.09
After Hours:
11.47
0.05
+0.44%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $11.42, with a volume of 7.81M.
It is up +0.79% in the last 24 hours and down -7.75% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$11.33
Open:
$11.45
24h Volume:
7.81M
Relative Volume:
0.96
Market Cap:
$13.63B
Revenue:
$15.05B
Net Income/Loss:
$-883.30M
P/E Ratio:
-15.43
EPS:
-0.74
Net Cash Flow:
$1.89B
1W Performance:
+2.51%
1M Performance:
-7.75%
6M Performance:
-5.85%
1Y Performance:
-3.30%
1-Day Range:
$11.30
$11.51
1-Week Range:
$11.06
$11.53
52-Week Range:
$9.925
$13.62
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.42 | 13.63B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
172.71 | 77.92B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.70 | 43.43B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.57 | 43.27B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.84 | 20.21B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
153.29 | 15.52B | 2.24B | 385.90M | 440.10M | 3.73 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments - MSN
VTRS: 3 Hidden Bargains in the Healthcare Sector - StockNews.com
Here's What to Expect From Viatris' Next Earnings Report - MSN
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Chris Davis Reduces Stake in Viatris Inc: A Strategic Portfolio Adjustment - GuruFocus.com
Viatris: Consolidate In 2025, Win In 2026How 'Phase 2' Of Business Plan May Play Out - Seeking Alpha
Here's What To Expect From Viatris' Next Earnings Report - Barchart
Lidocaine Patches Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Viatris Inc., Galen - EIN News
Shell says head of downstream and renewables division Vigeveno to step down -January 23, 2025 at 02:27 am EST - Marketscreener.com
Taxanes Market: Projected Growth Trends through 2031 | Pfizer - openPR
Why Is Viatris Inc. (VTRS) Among the Best High-Yield Dividend Stocks to Invest In? - Insider Monkey
EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com
Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN
Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com
Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance
Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Is Viatris (VTRS) the Best Medical Stock to Buy Under $20? - Insider Monkey
Viatris Enters Oversold Territory - Nasdaq
Viatris Stock: Is VTRS Outperforming the Healthcare Sector? - MSN
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Another Disappointing Drug Import Alert from India - The People's Pharmacy
When (VTRS) Moves Investors should Listen - Stock Traders Daily
US FDA Blocks 11 Viatris Products, Except Four With Shortage Concerns - News & Insights
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Con - GuruFocus.com
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference -January 07, 2025 at 07:00 am EST - Marketscreener.com
Maternal Mental Health Market Is Booming Worldwide 2025-2032 | - openPR
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris (VTRS) Shares Cross 4% Yield Mark - Nasdaq
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes (NASDAQ:VTRS) - Seeking Alpha
FDA Blocks Viatris US Products With India Facility Import Alert - News & Insights
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter - FiercePharma
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Viatris Inc. stock falls Monday, still outperforms market - MarketWatch
Maternal Mental Health Market Set to Witness Significant Growth by 2024-2031: Canopie, Pfizer Inc, Viatris - EIN News
Viatris Inc. stock falls Friday, still outperforms market - MarketWatch
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
1.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):